HER-2/neu genotype of breast cancer may change in bone metastasis

Tamás Lorincz, József Tóth, Gayane Badalian, József Tímár, Miklós Szendroi

Research output: Contribution to journalArticle

34 Citations (Scopus)


The genotype of breast cancer (BRC) is considered to be relatively stable during tumor progression, accordingly, determination of the estrogen receptor and HER-2/neu status is currently based on the primary tumor. However, recent data suggest that the gene expression profile of the metastatic lesion can be different compared to that of the primary BRC. Accordingly, it is possible that the HER-2/neu status is different in the metastatic lesion and the primary BRC. Since the bone is the most frequent metastatic site during the progression of BRC, we have analyzed the HER-2/neu status of 48 bone metastatic BRC cases by immunohistochemistry and fluorescent in situ hybridization, and it was possible to compare it to the primary site in 23 cases. The frequency of HER-2/neu amplification of BRC in the primary tumors was found to be 17.4% compared to 10.5% in bone metastases. Half of BRC cases with HER-2/neu amplification lost this genotype in bone metastases (4/23 versus 2/23, respectively) and even in the 2 cases where HER-2/neu amplification was retained in the metastases, the copy number was found to be decreased compared to the primary tumor. Based on our data and previous reports in the literature, we suggest to perform HER-2/neu testing both on primary tumor and samples obtained from BRC metastases, at least in case of primary tumors with HER-2/neu amplification, before introduction of HER-2/neu-targeting therapy.

Original languageEnglish
Pages (from-to)149-152
Number of pages4
JournalPathology and Oncology Research
Issue number3
Publication statusPublished - Jan 1 2006


  • Bone metastatic
  • Breast cancer
  • HER-2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'HER-2/neu genotype of breast cancer may change in bone metastasis'. Together they form a unique fingerprint.

  • Cite this